Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Muscle channelopathies and critical points in functional and genetic studies
Karin Jurkat-Rott, Frank Lehmann-Horn
Karin Jurkat-Rott, Frank Lehmann-Horn
Published August 1, 2005
Citation Information: J Clin Invest. 2005;115(8):2000-2009. https://doi.org/10.1172/JCI25525.
View: Text | PDF
Review Series Article has an altmetric score of 9

Muscle channelopathies and critical points in functional and genetic studies

  • Text
  • PDF
Abstract

Muscle channelopathies are caused by mutations in ion channel genes, by antibodies directed against ion channel proteins, or by changes of cell homeostasis leading to aberrant splicing of ion channel RNA or to disturbances of modification and localization of channel proteins. As ion channels constitute one of the only protein families that allow functional examination on the molecular level, expression studies of putative mutations have become standard in confirming that the mutations cause disease. Functional changes may not necessarily prove disease causality of a putative mutation but could be brought about by a polymorphism instead. These problems are addressed, and a more critical evaluation of the underlying genetic data is proposed.

Authors

Karin Jurkat-Rott, Frank Lehmann-Horn

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Proposed number of control chromosomes. A statistical algorithm helps to...
Proposed number of control chromosomes. A statistical algorithm helps to calculate the number of controls required to minimize the error. Let the prevalence of a mutation in patient chromosomes be p1 and the prevalence in control chromosomes be p0. Then the probability of an arbitrary control chromosome not carrying the mutation is (1 – p0). Because the world control population is large, the probability P of arbitrarily choosing n chromosomes thereof without the mutation may be approximated by P = (1 – p0)n. The null hypothesis would be that the mutation frequency is equal in patient and control chromosomes, i.e., p0 = p1 and P = (1 – p1)n. The number of control chromosomes to be tested can be calculated by resolution of the equation for the number n = ln(P)/ln(1 – p1). When the error probability P is set at 1%, the number of required control chromosomes is n = –4.6/ln(1 – p1) and n = 460 for the example of p1 = 1%. The curve demonstrates that 100 control individuals (200 chromosomes) would be adequate for a p1 of 2.5%, a prevalence that is much higher than that of the most frequent monogenic disorder. Adapted with permission from Neurology (90).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
Referenced in 7 Wikipedia pages
118 readers on Mendeley
1 readers on CiteULike
See more details